What's Happening?
Biopharma companies are increasingly investing in PD-(L)1×VEGF bispecific antibodies, which are seen as a promising next-generation immuno-oncology platform. These antibodies target both immune checkpoints and angiogenesis, potentially offering significant
benefits in treating various cancers. While lung cancer has been the primary focus, recent studies suggest that other cancers, such as hepatocellular carcinoma, may benefit more from these treatments. High-value deals, including Akeso's licensing of ivonescimab to Summit Therapeutics and Bristol Myers Squibb's partnership with BioNTech, highlight the industry's interest in these bispecifics. Despite promising progression-free survival data, a clear overall survival advantage has yet to be demonstrated, which is crucial for regulatory approval.
Why It's Important?
The exploration of PD-(L)1×VEGF bispecifics beyond lung cancer could significantly impact cancer treatment strategies. These antibodies offer a novel approach by combining checkpoint blockade and VEGF inhibition, potentially normalizing tumor vasculature and enhancing immune response. This could lead to more effective treatments for cancers where angiogenesis plays a critical role, such as hepatocellular carcinoma. The success of these bispecifics could shift the focus from lung cancer to other indications, providing new therapeutic options for hard-to-treat malignancies. The industry's substantial investment in this technology underscores its potential to reshape cancer treatment paradigms.
What's Next?
As biopharma companies continue to investigate PD-(L)1×VEGF bispecifics in various cancers, the focus will likely shift to demonstrating a robust overall survival benefit. Regulatory bodies like the FDA and European Medicines Agency require clear survival advantages for approval. Companies are conducting Phase 3 trials in indications such as colorectal, biliary tract, pancreatic, and triple-negative breast cancers. The success of these trials could lead to broader adoption of bispecifics in cancer treatment. Additionally, confirming China-origin data in multi-regional populations will be crucial for global practice-changing impact.
Beyond the Headlines
The development of PD-(L)1×VEGF bispecifics highlights the importance of biology-led indication selection. Prioritizing tumors with tightly intertwined angiogenesis and immune escape mechanisms could maximize the therapeutic potential of these antibodies. The nuanced success of these bispecifics suggests that their highest value may lie in cancers beyond lung cancer, where existing immuno-oncology combinations can be surpassed. This approach could lead to more personalized and effective cancer treatments, emphasizing the need for continued research and investment in innovative therapeutic strategies.
